Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/173874
Title: Validation of an Ex Vivo Permeation Method for the Intestinal Permeability of Different BCS Drugs and Its Correlation with Caco-2 In Vitro Experiments
Author: Sánchez, Aroha B.
Calpena Campmany, Ana Cristina
Mallandrich Miret, Mireia
Clares Naveros, Beatriz
Keywords: Medicació transdèrmica
Mucosa gastrointestinal
Disseny de medicaments
Transdermal medication
Gastrointestinal mucosa
Drug design
Issue Date: 29-Nov-2019
Publisher: MDPI
Abstract: The absorption study of drugs through different biological membranes constitutes an essential step in the development of new pharmaceutical dosage forms. Concerning orally administered forms, methods based on monolayer cell culture of Caco-2 (Caucasian colon adenocarcinoma) have been developed to emulate intestinal mucosa in permeability studies. Although it is widely accepted, it has disadvantages, such as high costs or high technical complexity, and limitations related to the simplified structure of the monolayer or the class of molecules that can be permeated according to the transport mechanisms. The aim of this work was to develop a new ex vivo methodology which allows the evaluation of the intestinal apparent permeability coefficient (Papp) while using fewer resources and to assess the correlation with Caco-2. To this end, pig (Sus scrofa) duodenum segments were mounted in Franz diffusion cells and used to permeate four different drugs: ketorolac tromethamine (Kt), melatonin (Mel), hydrochlorothiazide (Htz), and furosemide (Fur). No statistically significant differences (p > 0.05) were observed corelating Papp values from Franz diffusion cells and Caco-2 cell experiments for Kt, Htz, and Fur. However, there were statistically significant differences (p < 0.05) correlating Papp values and Mel. The difference is explained by the role of Mel in the duodenal epithelial paracellular permeability reduction. Ex vivo permeation may be an equivalent method to Caco-2 for drugs that do not produce intestinal membrane phenomena that could affect absorption.
Note: Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics11120638
It is part of: Pharmaceutics, 2019, vol. 11, num. 12, p. 638
URI: http://hdl.handle.net/2445/173874
Related resource: https://doi.org/10.3390/pharmaceutics11120638
ISSN: 1999-4923
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
694715.pdf3.79 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons